Results 171 to 180 of about 120,035 (227)

Significance of FEV₃/FEV₆ in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort. [PDF]

Chest, 2022
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK, Martinez FJ, Barr RG, Wells JM, Ortega VE, Hoffman EA, Kim V, Drummond MB, Bowler RP, Curtis JL, Cooper CB, Tashkin DP, Barjaktarevic IZ.   +21 more
europepmc   +1 more source

Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis. [PDF]

Commun Med (Lond)
Sena E, Tacke F, Anstee QM, Di Prospero N, Skalshøi-Kjær M, Muñoz-Martínez S, Rivera-Esteban J, Jiménez-Masip A, Bañales JM, Martínez-Gómez M, Koenig F, Genescà J, Ratziu V, Pericàs JM.   +13 more
europepmc   +1 more source

Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial. [PDF]

Chest, 2021
Labaki WW, Xia M, Murray S, Hatt CR, Al-Abcha A, Ferrera MC, Meldrum CA, Keith LA, Galbán CJ, Arenberg DA, Curtis JL, Martinez FJ, Kazerooni EA, Han MK.   +13 more
europepmc   +1 more source

Frequent Missed Opportunities for Earlier HIV Diagnosis in a Routine Opt-out Testing Environment in Atlanta. [PDF]

Open Forum Infect Dis
Gruber SF, Schwinne M, Iytha R, Hollenberg EJ, Robichaux C, Cantos VD, Colasanti JA, Yaffee AQ, Turbow S, Leue E, Camacho-González A, Wang YF, Lora MH.   +12 more
europepmc   +1 more source

COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. [PDF]

Microbiol Spectr
Habtehyimer F, Zhu X, Redd AD, Gebo KA, Abraham AG, Patel EU, Laeyendecker O, Gniadek TJ, Fernandez RE, Baker OR, Ram M, Cachay ER, Currier JS, Fukuta Y, Gerber JM, Heath SL, Meisenberg B, Huaman MA, Levine AC, Shenoy A, Anjan S, Blair JE, Cruser D, Forthal DN, Hammitt LL, Kassaye S, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Abinante M, Oei KS, Cluzet V, Cordisco ME, Greenblatt B, Rausch W, Shade D, Gawad AL, Klein SL, Pekosz A, Shoham S, Casadevall A, Bloch EM, Hanley D, Tobian AAR, Sullivan DJ.   +46 more
europepmc   +1 more source

Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme. [PDF]

BMJ Open Gastroenterol
Chaparro M, Panaccione R, Sands BE, Irving PM, Goetsch M, Kunina E, Wang W, Wu J, Woolcott JC, Bartolome L, Cognata C, Wosik K, Dubinsky MC.   +12 more
europepmc   +1 more source

The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort. [PDF]

ERJ Open Res
Agustí A, Hughes R, Rapsomaki E, Make B, Del Olmo R, Papi A, Price D, Benton L, Franzen S, Vestbo J, Mullerova H.   +10 more
europepmc   +1 more source

Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial. [PDF]

Chronic Obstr Pulm Dis
Hickman K, Tarabichi Y, Dickens AP, Pullen R, Kerr M, Couper A, Evans A, Gatenby J, Alves L, Ariti C, Bafadhel M, Carter V, Chalmers J, Chen R, Devereux G, Drummond MB, Gibson JM, Halpin DMG, Han M, Hanania NA, Hurst JR, Kaplan A, Kostikas K, Make B, Mapel D, Marshall J, Martinez F, Meldrum C, van Melle M, Miravitlles M, Morris T, Mullerova H, Murray R, Muro S, Nordon C, Ohar J, Pace W, Pollack M, Quint JK, Sharma A, Singh D, Singh M, Trudo F, Williams D, Wilkinson T, Winders T, Price D.   +46 more
europepmc   +1 more source

NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis. [PDF]

J Patient Rep Outcomes
Doward LC, Breckons M, Balp MM, Twiss J, Vale L, McSweeney L, Brass CA, Anstee QM, Sanyal AJ.   +8 more
europepmc   +1 more source